HCAb Plus™


Idea to IND

Beacon® Single B Cell Screening

Our Beacon® Platforms and Technology

High Throughput Screening
Antibody Discovery by Beacon® Technology
SCB Platform Workflow
hyperSCREEN: AI-Guided Screening

High Throughput Screening

Nona Biosciences has developed cutting-edge high-throughput screening platforms to expedite antibody discovery.

Since early 2019, our scientific team has established a single B cell cloning (SBC) platform using Berkeley Lights Beacon® Optofluidic technology. We have accumulated substantial expertise in Beacon® and SBC through dozens of antibody discovery projects. Leveraging optimized murine plasma cell enrichment methods, robust and reliable in-chip assay development process, highly efficient single cell sequencing technology, and high-throughput recombinant antibody screening techniques, we’ve successfully applied our SBC platform to more than 50 different antibody generation projects with shortened screening timeline and increased sequence diversity.

We’ve also optimized an innovative high-throughput technology for rapid direct cloning and production of fully human HCAbs from B cells of HCAb Harbour Mice®, which was originally developed in 2016 (Drabek, D. et al. Frontiers in Immunology 7, 3–12 (2016)). This technology facilitates the production of fully human HCAbs in 96-well plates and expedites the process of functional screening.

Despite the capacity of these high-throughput technologies to rapidly screen tens of thousands of B cells and provide a wide array of sequences we are highly motivated to embrace new technologies, such as artificial intelligence (AI), to further increase the screening efficiency and sequence diversity. Through the integration of next-generation sequencing and machine learning, we can explore a more extensive sequence space and uncover sequences that cannot be easily identified by other screening methods.

HCAb-based TAA×CD3 Bispecific T cell Engagers

mRNA with HCAb PLUS™

Nona Biosciences, our dedicated team designed HCAb-based TAA×CD3 bispecific T cell engagers, synthesized the corresponding mRNA in vitro, and encapsulated it in lipid nanoparticles (LNPs). Notably, the mRNA-encoded TAA×CD3 engager showcased robust cytotoxicity against target cells in both in vitro and in vivo settings.

High Throughput Chip

Each 20K OptoSelect chip has 20,000 individual NanoPen chambers and can separate and screen up to 20,000 cells within a single run.

Versatile In-Chip Assays

With real-time fluorescent microscopy technology, different assays could be performed in-chip for plasma cell screening, including:

  • Antigen beads binding assay
  • Cell binding assay
  • Competition assay
  • Reporter cell assay

All these advantages make SBC platform to become highly efficient and robust antibody discovery platform.

Precisely Single Cell Exporting

Opto-electro positioning (OEP) technology precisely manipulates and unloads cells to 96-well plates preloaded with single-cell sequencing reagents.

Precisely Single Cell Exporting

Opto-electro positioning (OEP) technology precisely manipulates and unloads cells to 96-well plates preloaded with single-cell sequencing reagents.

The outcomes are genuinely extraordinary

  • HCAb format of TAA demonstrates exceptional flexibility in designing T cell engagers and can be readily converted into mRNA-LNP format.

  • TAA×CD3 mRNA-LNP exhibits robust cytotoxicity against TAA-expressing target cells.

  • TAA×CD3 mRNA-LNP demonstrates remarkable anti-tumor efficacy in human PBMC humanized mouse model.

TAA×CD3 mRNA-LNP Generation
Beacon® Plasma Cell Workflow
Step one

Antibody Discovery

Leveraging Harbour Mice® platforms and expertise, Nona provides a complete solution for fully human H2L2, HCAb, and bi/multi-specific antibody discovery, including antigen preparations, immunization, antibody screening, engineering, and functional evaluation.

Step two

ADC Bioconjugation

Nona offers a variety of bioconjugation technologies such as lysine/cysteine-based conjugation with optimized DAR value and optimization of reaction conditions. Our proprietary DAR2 site-specific conjugation and linker-payload library include the majority of classical linker-payloads, like cleavable and non-cleavable linkers.

step Three

ADC Biophysical Characterizations

Based on Nona’s deep understanding of ADC molecules, we perform a comprehensive assessment of molecules for lead identification and characterization, including DAR determination, conjugation stability, plasma stability and drug-releasing efficiency.

In Vitro
In Vivo
Step four

ADC In Vitro and In Vivo Characterization

A full range of in vitro bioactivity studies for both monoclonal antibodies and ADCs is available, including antigen binding, internalization, soluble antigen interference, cytotoxicity, and bystander killing. Nona also encompasses integral capabilities for in vivo studies, including various pharmacological models for ADC efficacy assessment, such as CDX, PDX, and heterogeneous tumor models. Additionally, pre-toxicity evaluation and small animal PK studies complete the integrated ADC R&D services.


Lorem ipsum dolor sit amet consectetur. Nibh malesuada.

Lorem ipsum dolor sit amet consectetur. Quis ultricies accumsan aliquet pulvinar leo magnis sit porttitor. Habitant venenatis risus.

Lorem ipsum dolor sit amet consectetur. Tincidunt integer.

Lorem ipsum dolor sit amet consectetur. Et sed.

Lorem ipsum dolor sit amet consectetur. Viverra sed arcu elementum integer adipiscing. Egestas lorem vitae elit malesuada luctus enim justo enim vestibulum. Consectetur malesuada sit feugiat quam quam consequat bibendum aliquam dictum. Ullamcorper volutpat a commodo ornare vitae tortor gravida. Massa massa metus senectus ac sit fermentum nunc nulla. Gravida gravida iaculis potenti ut quam.

Explore Our Other High Lighted Technologies

Explore our lorem ipsum

Start your Harbour Mice HCAb PLUS™ Project

Having questions? Contact us at


Privacy Settings
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please check our Privacy Policy
Consent to display content from - Youtube
Consent to display content from - Vimeo
Google Maps
Consent to display content from - Google
Consent to display content from - Spotify
Sound Cloud
Consent to display content from - Sound